|

Bevacizumab Clinical Trials

205 actively recruiting trials across 49 locations

No change since July 2026

Also known as: - Alymsys®, - Avastin®, - Aybintio®, - Breztri®, - MVASI® +113 more

Pipeline

Early 1: 1Phase 1: 34Phase 2: 82Phase 3: 39Phase 4: 4Phase 1/2: 35Phase 2/3: 5

Top Sponsors

  • Sun Yat-sen University10
  • Fudan University8
  • AbbVie8
  • Merck Sharp & Dohme LLC5
  • M.D. Anderson Cancer Center5

Indications

Other101 trials

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
Phase 2
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
Phase 1/2
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
Phase 1/2
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
Phase 1
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
Phase 2
A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer
Phase 2
A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
Phase 1/2
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
Phase 2
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Phase 1/2
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Phase 1/2
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
Phase 3
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Phase 3
A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer
Phase 3
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
Phase 3
A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
Phase 2
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Phase 2
A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors
Phase 2
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Phase 3
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Phase 2/3
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
Phase 3
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Phase 2
AB122 Platform Study
Phase 1
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Phase 3
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
Phase 1
Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients
Phase 3
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
Phase 2
Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma
Phase 2
Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
Phase 3
Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases
Phase 3
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer
Phase 2
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer
Phase 2
Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer
Phase 4
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Phase 2
Combination Therapy for BRAF-V600E Metastatic CRCm
Phase 2
Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer
Phase 3
Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases
Phase 3
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
N/A
Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
Phase 2
Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
Phase 2
Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial
Phase 2
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
Phase 4
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Phase 2
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Phase 2
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
Phase 2
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
Phase 3
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Phase 1
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
Phase 2
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
Phase 2
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
Phase 3
HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
N/A
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors
Phase 1
Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)
Phase 2
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
Phase 2
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Phase 2
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
N/A
Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression
Phase 2
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Phase 1
JS212 Combination Therapies in Metastatic Colorectal Cancer
Phase 2
Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV
Phase 1/2
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
Phase 2
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
Phase 1/2
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
Phase 2
Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
Phase 2
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Phase 2/3
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
Phase 3
ONO-4538 Phase II Rollover Study (ONO-4538-98)
Phase 2
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
Phase 2
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
Phase 2
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
Phase 2
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer
Phase 2
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
Phase 1
Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
N/A
QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
Phase 2
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
Phase 2
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
Phase 2
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
Phase 2
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
Phase 2/3
SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC
Phase 3
SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer(CRIT)
Phase 2
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Phase 2
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
Phase 2
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
Phase 2
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
Phase 2
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
Phase 1/2
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
Phase 2
Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
Phase 2
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
Phase 2
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
Phase 1/2
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
Phase 2
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Phase 2
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Phase 3
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
Phase 3
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
Phase 2
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study
Phase 2
The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites
Phase 2
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
Phase 1/2
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Phase 1/2
Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
Phase 2
Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
Phase 2
Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
Phase 2
Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer
Phase 2

Birmingham, Alabama11 trials

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

UAB Comprehensive Cancer Center

Phase 1
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

The Kirklin Clinic of University of Alabama Birmingham Hospital

Phase 1/2
A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

University of Alabama at Birmingham

Phase 1/2
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

University of Alabama at Birmingham (UAB) Hospital /ID# 274793

Phase 2
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

University of Alabama at Birmingham ( Site 0006)

Phase 3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

University of Alabama at Birmingham

Phase 3
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

The University of Alabama at Birmingham

Phase 2
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

University of Alabama at Birmingham Cancer Center

Phase 3
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

University of Alabama at Birmingham Cancer Center

Phase 3
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

University of Alabama at Birmingham Cancer Center

Phase 3
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer

University of Alabama at Birmingham

Phase 1

Duarte, California10 trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope

Phase 1/2
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

City of Hope Comprehensive Cancer Center

Phase 1/2
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

City of Hope /ID# 261468

Phase 2/3
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

City of Hope National Medical Center /ID# 270255

Phase 2
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Local Institution - 0137

Phase 1/2
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

City of Hope Cancer Center

Phase 1
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

City of Hope Comprehensive Cancer Center

Phase 1
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Research Site

Phase 1/2
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

City of Hope National Medical Center /ID# 276272

Phase 1

Los Angeles, California9 trials

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Los Angeles Hematology Oncology Medical Group ( Site 0084)

Phase 3
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

Local Institution - 0007

Phase 1/2
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

The Angeles Clinic and Research Institute

Phase 1
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 1/2
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

UCLA Medical Center

Phase 2
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Usc Norris Comprehensive Cancer Center (Nccc)

Phase 1
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

Angeles Clinic and Research Center

Phase 1/2
Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Research Site

Phase 2

Houston, Texas6 trials

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

Houston Methodist Neal Cancer Center

Phase 2
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

Houston Methodist Research Institute

Phase 4
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

M D Anderson Cancer Center

Phase 1
Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

MD Anderson Cancer Center

Phase 1
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

M D Anderson Cancer Center

Phase 1
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

MD Anderson Cancer Center

Phase 1

Phoenix, Arizona5 trials

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Mayo Clinic Hospital

Phase 1
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Mayo Clinic Arizona

Phase 2
FOG-001 in Locally Advanced or Metastatic Solid Tumors

Mayo Clinic

Phase 1/2
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Research Site

Phase 3
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

USOR HonorHealth

Phase 1/2

Scottsdale, Arizona5 trials

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

HonorHealth

Phase 1
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Research Site

Phase 2
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Mayo Clinic in Arizona

Phase 1/2
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

HonorHealth Research Institute

Phase 1
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Mayo Clinic in Arizona

Phase 2

Chandler, Arizona3 trials

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Ironwood Cancer and Research Center

Phase 3
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Ironwood Cancer and Research Centers

Phase 1/2
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Ironwood Cancer & Research Centers

Phase 3

La Jolla, California3 trials

A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)

GSK Investigational Site

Phase 1/2
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

UC San Diego Health - Moores Cancer Center /ID# 277574

Phase 2
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

UC San Diego Moores Cancer Center

Phase 2

New Haven, Connecticut3 trials

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)

Phase 1/2
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

Yale University

Phase 1/2
A Study of ASP1002 in Adults for Treatment of Solid Tumors

Yale University Cancer Center

Phase 1

New York, New York3 trials

Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant

Icahn School of Medicine at Mount Sinai

Phase 4
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Memorial Sloan Kettering Cancer Center

Phase 2
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

Lenox Hill Brain Tumor Center

Phase 1/2

Goodyear, Arizona2 trials

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

City of Hope Phoenix Cancer Center

Phase 1
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

CTCA at Western Regional Medical Center

Phase 2

Tucson, Arizona2 trials

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

The University of Arizona Cancer Center

Phase 3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Local Institution - 0428

Phase 2/3

Beverly Hills, California2 trials

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Precision NextGen Oncology

Phase 1/2
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Beverly Hills Cancer Center

Phase 2

Aurora, Colorado2 trials

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

Site 0264

Phase 1
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

University of Colorado Denver Anschultz Medical Campus

Phase 1

Denver, Colorado2 trials

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer

Sarah Cannon Research Institute at HealthONE /ID# 278785

Phase 1
First In Human Study of CX-2051 in Advanced Solid Tumors

Sarah Cannon Research Institute at HealthONE

Phase 1

Miami, Florida2 trials

Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma

University of Miami

N/A
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

Mt. Sinai Comprehensive Cancer Center

Phase 3

Buffalo, New York2 trials

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Roswell Park Cancer Institute

Phase 2
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Roswell Park Cancer Institute

Phase 2

Homewood, Alabama1 trial

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Central Alabama Research

Phase 2

Huntsville, Alabama1 trial

Pan Tumor Rollover Study

Local Institution - 0220

Phase 2

Anchorage, Alaska1 trial

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Anchorage Associates in Radiation Medicine

Phase 3

Glendale, Arizona1 trial

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Palo Verde Hematology Oncology

Phase 3

Little Rock, Arkansas1 trial

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

University of Arkansas - Winthrop P. Rockefeller Cancer Institute

Phase 1

Berkeley, California1 trial

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Alta Bates Summit Medical Center-Herrick Campus

Phase 3

Burbank, California1 trial

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

Disney Family Cancer Center

Phase 3

Irvine, California1 trial

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

University of California, Irvine (UCI) Health - UC Irvine Medical Center

Phase 1/2

Long Beach, California1 trial

Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence

Miller Children's and Women's Hospital Long Beach

Early 1

Santa Monica, California1 trial

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

John Wayne Cancer Center at Providence St. John's Health Center

Phase 2

Stanford, California1 trial

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

GSK Investigational Site

Phase 1

Lone Tree, Colorado1 trial

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Rocky Mountain Cancer Centers, LLP- Aurora

Phase 3

Danbury, Connecticut1 trial

Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

Danbury Hospital

Phase 3

North Haven, Connecticut1 trial

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

Yale-New Haven Hospital - Yale Cancer Center

Phase 2

Newark, Delaware1 trial

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Christiana Care Health System - Newark- Site Number : 8400011

Phase 1/2

Washington D.C., District of Columbia1 trial

Evaluating Novel Therapies in ctDNA Positive GI Cancers

Georgetown Lombardi Comprehensive Cancer Center

Phase 3

Fort Myers, Florida1 trial

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Florida Cancer Specialists - South ( Site 7001)

Phase 3

Gainesville, Florida1 trial

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

UF Health Cancer Institute - Gainesville

Phase 1

Miami Beach, Florida1 trial

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Mount Sinai Cancer Center ( Site 0029)

Phase 3

Chicago, Illinois1 trial

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Ann & Robert H. Lurie Children's Hospital of Chicago

Phase 2

Iowa City, Iowa1 trial

Sitagliptin in Recurrent/Progressive Grade 4 Glioma

University of Iowa Health Care

Phase 1

Baltimore, Maryland1 trial

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Johns Hopkins Medicine SKCCC

Phase 1/2

Boston, Massachusetts1 trial

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Massachusetts General Hospital

Phase 1

Rochester, Minnesota1 trial

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Mayo Clinic in Rochester

Phase 1/2

East Brunswick, New Jersey1 trial

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

Astera Cancer Care /ID# 279532

Phase 3

Teaneck, New Jersey1 trial

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Holy Name Medical Center /ID# 279017

Phase 2

Lake Success, New York1 trial

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

GSK Investigational Site

Phase 1

Charleston, South Carolina1 trial

Autophagy Maintenance (AUTOMAIN)

Medical University of South Carolina

Phase 2

Germantown, Tennessee1 trial

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Methodist Le Bonheur Healthcare

Phase 1/2

Charlottesville, Virginia1 trial

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

University of Virginia

Phase 1/2

Fairfax, Virginia1 trial

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

Inova Schar Cancer Institute - Fair Oaks

Phase 2

Madison, Wisconsin1 trial

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

University of Wisconsin Carbone Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.